[{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Deerfield Management Company"},{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Deerfield Management Company"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2025","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"BiomX \/ Laidlaw & Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Laidlaw & Company"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The Company intends to use the proceeds to support the completion of the Phase 2b of BX004, BiomX’s fixed phage cocktail, for the treatment of people with CF with chronic pulmonary infections.

                          Product Name : BX004

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          February 26, 2025

                          Lead Product(s) : BX004

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Laidlaw & Company

                          Deal Size : $12.0 million

                          Deal Type : Private Placement

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The proceeds will fund Phase 2b for BX004 in chronic pulmonary infections in CF patients and Phase 2 results from APT’s clinical-stage BX211, for the treatment of S. aureus infections.

                          Product Name : BX004

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          June 03, 2024

                          Lead Product(s) : BX004

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Deerfield Management Company

                          Deal Size : $50.0 million

                          Deal Type : Private Placement

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Proceeds fund BX004 for chronic pulmonary infections in CF patients and BX211 for S. aureus in Phase 2.

                          Product Name : BX004

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          March 18, 2024

                          Lead Product(s) : BX004

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Deerfield Management Company

                          Deal Size : $50.0 million

                          Deal Type : Private Placement

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SPL84, has shown to have completely restored CFTR activity in the CF gold standard pharmacological model, suggesting potential cure for these patients.

                          Product Name : SPL84

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          December 14, 2022

                          Lead Product(s) : SPL84

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : In vitro results demonstrate that BiomX’s phage cocktail, BX004, was able to penetrate biofilm and was efficacious in significantly reducing bacterial levels of Pseudomonas aeruginosa encased in biofilm, relative to two different antibiotics.

                          Product Name : BX004

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          September 06, 2021

                          Lead Product(s) : BX004

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank